The combined use of HA380 hemoperfusion in cardiopulmonary bypass alleviates postoperative inflammatory response and organ dysfunction following cardiac surgery
Year: 2026
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: OBJECTIVE: To evaluate the efficacy of the HA380 hemoperfusion device in attenuating systemic inflammatory response during cardiopulmonary bypass (CPB)-assisted cardiac surgery and its influence on perioperative clinical outcomes. METHODS: This trial enrolled 65 patients who underwent elective cardiac surgery with CPB. Patients were randomly divided into two groups: the experimental group (HP group, n = 34) used the HA380 hemoperfusion device throughout CPB; the control group (n = 31) underwent conventional CPB only. Serum levels of IL-1β, IL-6, IL-8, IL-10, TNF-α, and CRP were measured at: preoperatively (T0), immediately postoperatively (T1), 24 h (T2) and 48 h (T3) post-surgery. Surgical data, postoperative ICU indicators (duration of intubation, vasoactive-inotropic score [VIS], drainage volume, urine output, ICU stay duration), and first-day postoperative blood routine, liver and kidney function, and coagulation indicators were recorded. Differences between the two groups were compared. RESULTS: There were no statistical differences in baseline data between the two groups (P > 0.05). Inflammatory factor analysis showed that serum levels of IL-1β, IL-6, IL-8, and IL-10 in the HP group were significantly lower than the control group (P < 0.05) at T1 and T2. However, no significant differences were observed in TNF-α and CRP levels between the two groups at any time point (P > 0.05). Regarding clinical indicators, the HP group exhibited a lower VIS on postoperative day 1 (P < 0.05); significant reductions in levels of white blood cells, neutrophils, ALT, urea, and creatinine were observed than the control group (P < 0.05). ICU intubation time, drainage volume, and urine output on the first postoperative day, ICU stay duration, hemoglobin, platelet, bilirubin, and other indicators showed no intergroup differences (P > 0.05). CONCLUSION: The combined application of the HA380 blood perfusion device during CPB-assisted cardiac surgery effectively clears medium molecular weight inflammatory mediators (IL-1β, IL-6, IL-8, IL-10), significantly reduces early postoperative systemic inflammatory response, and helps improve early postoperative hemodynamic stability (reducing the need for vasoactive drugs) and short-term liver and kidney function indicators. However, no significant reduction was observed in ICU mechanical ventilation time and ICU stay duration. HA380 demonstrates promise as an adjunct anti-inflammatory therapy, though its long-term benefits and impact on postoperative recovery optimization require further investigation.
Authors: Longlong Li, Jing Li, Hui Li, Suli Wang, Chunyu Chen, Biao Zhang
Institution: Anhui Medical University
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,890
OpenAlex ID: W7148892363